Study design and treatment
toxicity, tumour
TUMOUR
Patients received the PD‐L1 inhibitor atezolizumab concomitant with SBRT. Atezolizumab was administered at a fixed dose of 1200 mg intravenously every 3 weeks for a maximum of 2 years until intolerable toxicity or no clinical benefit as judged by the investigator. SBRT 6 Gy × 3, fractions 1 day apart, was given towards one or two tumour lesions, minimum 2 cm